



#15.102

Docket No.: PC-0022 CIP

Response Under 37 C.F.R. 1.116 - Expedited Procedure
Examining Group 1648

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop: Appeal Brief-Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 4, 2003.

By: [Signature]

Printed: D. Ellis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**

In re Application of: Tang et al.

Title: GROWTH-RELATED INFLAMMATORY AND IMMUNE RESPONSE
PROTEIN

Serial No.: 09/747,524

Filing Date: December 19, 2000

Examiner: Hill, M.

Group Art Unit: 1648

Mail Stop: Appeal Brief-Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BRIEF ON APPEAL

Sir:

Further to the Notice of Appeal filed March 31, 2003, and received by the USPTO on April 7, 2003, herewith are three copies of Appellants' Brief on Appeal. Authorized fees include the \$ 320.00 fee for the filing of this Brief.

This is an appeal from the decision of the Examiner finally rejecting claims 1-6 of the above-identified application.

(1) REAL PARTY IN INTEREST

The above-identified application is assigned of record Incyte Pharmaceuticals, Inc., (now Incyte Corporation, formerly known as Incyte Genomics, Inc.) (Reel 011782, Frame 0481) which is the real party in interest herein.

(2) RELATED APPEALS AND INTERFERENCES

Appellants, their legal representative and the assignee are not aware of any related appeals or interferences which will directly affect or be directly affected by or have a bearing on the Board's decision in the instant appeal.

(3) STATUS OF THE CLAIMS

Claims rejected: Claims 1-6
Claims allowed: (none)
Claims canceled: (none)
Claims withdrawn: Claims 7-20
Claims on Appeal: Claims 1-6 (A copy of the claims on appeal, as amended, can be found in the attached Appendix).

(4) STATUS OF AMENDMENTS AFTER FINAL

There were no amendments submitted after Final Rejection.

(5) SUMMARY OF THE INVENTION

Appellants' invention is directed to polynucleotides encoding a growth-related and immune response protein (GRIIP; SEQ ID NO:1). GRIIP was first identified as a cell cycle gene by a strong association, or coexpression, with known genes that are specific to the cell cycle. See specification at p. 9, lines 12-22. GRIIP was identified as a tissue injury associated molecule by a high level of sequence identity (79%) with a rat kidney injury associated molecule, HW051, and by conservation of various sequence domains and protein motifs between the two proteins. See specification at p. 10. GRIIP was further characterized by high expression in inflammation and immune response tissues, in particular, with cancers of the immune system. See specification at pp. 9-10 and Figures 3A and 3B. The claimed polynucleotides are therefore asserted to be useful in the diagnosis and treatment of disorders associated with inflammation and the immune response, particularly cancers of the immune system (specification at pp. 18 and 19), and in toxicology testing and drug discovery (specification at pp. 20-23).

(6) ISSUES

1. Whether claims 1-6 directed to a GRIIP-encoding polynucleotide sequences meet the enablement requirement of 35 U.S.C. §112, first paragraph. Whether one of ordinary skill in the art would know how to use the claimed sequences, e.g., in toxicology testing, drug development, and the diagnosis or treatment of disease, so as to satisfy the enablement requirement of 35 U.S.C. §112, first paragraph.

(7) GROUPING OF THE CLAIMS

As to Issue 1

All of the claims on appeal are grouped together.

(8) APPELLANTS' ARGUMENTS

The rejection of Claims 1-6 is improper, as the specification provides an adequate enabling disclosure for the claimed subject matter to one of skill in the art.

The rejection alleges in particular that:

applicant asserts that the cDNA and protein are useful in the diagnosis and treatment of disorders associated with inflammation (page 3, lines 7-9). Figure 3A shows that this DNA is expressed in many tissue types and Figure 3B shows that it is expressed in samples from several lymphoid tissues, most with cancer related conditions. However, one skilled in the art would have reason to doubt the usefulness of the DNA (or protein) for diagnosis or treatment of diseases or disorders associated with inflammation and the immune response (list in specification page 19, lines 4-22). Considering the long list of possible diseases, drawn to many different populations having conditions with different symptoms and disease endpoints, the amount of work needed to establish the association/correlation of a particular disease state, the very general nature of the teachings in the specification, and lack of working examples that show the ability to specifically diagnose a specific condition or treat a condition in a specific way, it is considered to require undue experimentation to use the invention. See Office Action, mailed 5/31/2002 at pp. 3-4.

The invention at issue is a polynucleotide sequence corresponding to a gene that is expressed in humans, in particular, with tissues of the hemic and immune system. The novel polynucleotide codes for a polypeptide demonstrated in the patent specification to be associated with tissue injury. See specification, at p. 10. As such, the claimed invention has numerous practical, beneficial uses in toxicology testing, drug development, and the diagnosis of disease, none of which requires knowledge of how the polypeptide coded for by the polynucleotide actually functions.

Appellants submit with this brief the Declaration of Bedilion describing some of the practical uses of the claimed invention in gene and protein expression monitoring applications. The Bedilion Declaration demonstrates that the positions and arguments made by the Patent Examiner with respect to the lack of enabling uses of the claimed polynucleotide are without merit.

The Bedilion Declaration describes, in particular, how the claimed expressed polynucleotide can be used in gene expression monitoring applications that were well-known at the time the patent application was filed, and how those applications are useful in developing drugs and monitoring their activity. Dr. Bedilion states that the claimed invention is a useful tool when employed as a highly specific probe in a cDNA microarray:

Persons skilled in the art would have appreciated on August 30, 2000 that cDNA microarrays that contained the SEQ ID NO:1-encoding polynucleotides would be a more useful tool than cDNA microarrays that did not contain the polynucleotides in connection with conducting gene expression monitoring studies on proposed (or actual) drugs for treating cancer and immune disorders for such purposes as evaluating their efficacy and toxicity. (Bedilion Declaration, ¶ 15.)

The Patent Examiner does not dispute that the claimed polynucleotide can be used as a probe in cDNA microarrays and used in gene expression monitoring applications. Instead, the Patent Examiner contends that the claimed polynucleotide cannot be useful without more detailed clinical studies and statistical analyses. But the law has never required proof of the use of a claimed invention to certainty, a "substantial likelihood" is all that is required. See "The Applicable Legal Standard" below.

In any event, as demonstrated by the Bedilion Declaration, the person of ordinary skill in the art can achieve beneficial results from the claimed polynucleotide in the absence of any knowledge from clinical studies regarding its specific use as a marker for any particular disease condition.

I. The Applicable Legal Standard

To meet the utility requirement of sections 101 and 112 of the Patent Act, the patent applicant need only show that the claimed invention is “practically useful,” *Anderson v. Natta*, 480 F.2d 1392, 1397, 178 USPQ 458 (CCPA 1973) and confers a “specific benefit” on the public. *Brenner v. Manson*, 383 U.S. 519, 534-35, 148 USPQ 689 (1966). As discussed in a recent Court of Appeals for the Federal Circuit case, this threshold is not high:

An invention is “useful” under section 101 if it is capable of providing some identifiable benefit. See *Brenner v. Manson*, 383 U.S. 519, 534 [148 USPQ 689] (1966); *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571 [24 USPQ2d 1401] (Fed. Cir. 1992) (“to violate Section 101 the claimed device must be totally incapable of achieving a useful result”); *Fuller v. Berger*, 120 F. 274, 275 (7th Cir. 1903) (test for utility is whether invention “is incapable of serving any beneficial end”). *Juicy Whip Inc. v. Orange Bang Inc.*, 51 USPQ2d 1700 (Fed. Cir. 1999).

While an asserted utility must be described with specificity, the patent applicant need not demonstrate utility to a certainty. In *Stiftung v. Renishaw PLC*, 945 F.2d 1173, 1180, 20 USPQ2d 1094 (Fed. Cir. 1991), the United States Court of Appeals for the Federal Circuit explained:

An invention need not be the best or only way to accomplish a certain result, and it need only be useful to some extent and in certain applications: “[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding lack of utility.” *Envirotech Corp. v. Al George, Inc.*, 730 F.2d 753, 762, 221 USPQ 473, 480 (Fed. Cir. 1984).

The specificity requirement is not, therefore, an onerous one. If the asserted utility is described so that a person of ordinary skill in the art would understand how to use the claimed invention, it is sufficiently specific. See *Standard Oil Co. v. Montedison, S.p.a.*, 212 U.S.P.Q. 327, 343 (3d Cir. 1981). The specificity requirement is met unless the asserted utility amounts to a “nebulous expression” such as “biological activity” or “biological properties” that does not convey meaningful information about the utility of what is being claimed. *Cross v. Iizuka*,

753 F.2d 1040, 1048 (Fed. Cir. 1985).

In addition to conferring a specific benefit on the public, the benefit must also be “substantial.” *Brenner*, 383 U.S. at 534. A “substantial” utility is a practical, “real-world” utility. *Nelson v. Bowler*, 626 F.2d 853, 856, 206 USPQ 881 (CCPA 1980).

If persons of ordinary skill in the art would understand that there is a “well-established” utility for the claimed invention, the threshold is met automatically and the applicant need not make any showing to demonstrate utility. Manual of Patent Examination Procedure at § 706.03(a). Only if there is no “well-established” utility for the claimed invention must the applicant demonstrate the practical benefits of the invention. *Id.*

Once the patent applicant identifies a specific utility, the claimed invention is presumed to possess it. *In re Cortright*, 165 F.3d 1353, 1357, 49 USPQ2d 1464 (Fed. Cir. 1999); *In re Brana*, 51 F.3d 1560, 1566; 34 USPQ2d 1436 (Fed. Cir. 1995). In that case, the Patent Office bears the burden of demonstrating that a person of ordinary skill in the art would reasonably doubt that the asserted utility could be achieved by the claimed invention. *Id.* To do so, the Patent Office must provide evidence or sound scientific reasoning. *See In re Langer*, 503 F.2d 1380, 1391-92, 183 USPQ 288 (CCPA 1974). If and only if the Patent Office makes such a showing, the burden shifts to the applicant to provide rebuttal evidence that would convince the person of ordinary skill that there is sufficient proof of utility. *Brana*, 51 F.3d at 1566. The applicant need only prove a “substantial likelihood” of utility; certainty is not required. *Brenner*, 383 U.S. at 532.

II. The uses of the claimed polynucleotides for the diagnosis of diseases or conditions characterized by GRIIP expression, for toxicology testing and for drug discovery are sufficient utilities under 35 U.S.C. §§ 101 and 112, first paragraph

The claimed invention meets all of the necessary requirements for establishing a credible utility under the Patent Law: There are “well-established” uses for the claimed invention known to persons of ordinary skill in the art, and there are specific practical and beneficial uses for the invention disclosed in the patent application’s specification. These uses are explained, in detail, in the Bedilion Declaration accompanying this brief. Objective evidence, not considered by the Patent Office, further corroborates the credibility of the asserted utilities.

A. The use of claimed polynucleotides for toxicology testing, drug discovery, and disease diagnosis are practical uses that confer “specific benefits” to the public

The claimed invention has specific, substantial, real-world utility by virtue of its use in toxicology testing, drug development and disease diagnosis through gene expression profiling. These uses are explained in detail in the accompanying Bedilion Declaration, the substance of which is not rebutted by the Patent Examiner. There is no dispute that the claimed invention is in fact a useful tool in cDNA microarrays used to perform gene expression analysis. That is sufficient to establish utility for the claimed polynucleotide.

In his Declaration, Dr. Bedilion explains the many reasons why a person skilled in the art reading the Walker '253 application on August 30, 2000 would have understood that application to disclose the claimed polynucleotide to be useful for a number of gene expression monitoring applications, *e.g.*, as a highly specific probe for the expression of that specific polynucleotide in connection with the development of drugs and the monitoring of the activity of such drugs (Bedilion Declaration at, *e.g.*, ¶¶ 10-15). Much, but not all, of Dr. Bedilion's explanation concerns the use of the claimed polynucleotide in cDNA microarrays of the type first developed at Stanford University for evaluating the efficacy and toxicity of drugs, as well as for other applications (Bedilion Declaration, ¶¶ 12 and 15).¹

In connection with his explanations, Dr. Bedilion states that the “Walker '253 specification would have led a person skilled in the art on August 30, 2000 who was using gene expression monitoring in connection with working on developing new drugs for the treatment of cancer and immune disorders [a] to conclude that a cDNA microarray that contained the SEQ ID NO:1-encoding polynucleotides would be a highly useful tool, and [b] to request specifically that any cDNA microarray that was being used for such purposes contain the SEQ ID NO:1-encoding polynucleotides” (Bedilion Declaration, ¶ 15). For example, as explained by Dr. Bedilion, “[p]ersons skilled in the art would appreciate on August 30, 2000 that a cDNA microarray that

¹Dr. Bedilion also explained, for example, why persons skilled in the art would also appreciate, based on the Walker '253 specification, that the claimed polynucleotide would be useful in connection with developing new drugs using technology, such as Northern analysis, that predated by many years the development of the cDNA technology (Bedilion Declaration, ¶ 16).

contained the SEQ ID NO:1-encoding polynucleotides would be a more useful tool than a cDNA microarray that did not contain the polynucleotides in connection with conducting gene expression monitoring studies on proposed (or actual) drugs for treating cancer and immune disorders for such purposes as evaluating their efficacy and toxicity.” *Id.*

In support of those statements, Dr. Bedilion provided detailed explanations of how cDNA technology can be used to conduct gene expression monitoring evaluations, with extensive citations to pre-August 30, 2000 publications showing the state of the art on August 30, 2000 (Bedilion Declaration, ¶¶ 10-14). While Dr. Bedilion’s explanations in paragraph 15 of his Declaration include three pages of text and six subparts [(a)-(f)], he specifically states that his explanations are not “all-inclusive.” *Id.* For example, with respect to toxicity evaluations, Dr. Bedilion had earlier explained how persons skilled in the art who were working on drug development on August 30, 2000 (and for several years prior to August 30, 2000) “without any doubt” appreciated that the toxicity (or lack of toxicity) of any proposed drug was “one of the most important criteria to be evaluated in connection with the development of the drug” and how the teachings of the Walker '253 application clearly include using differential gene expression analyses in toxicity studies (Bedilion Declaration, ¶ 10).

Thus, the Bedilion Declaration establishes that persons skilled in the art reading the Walker '253 application at the time it was filed “would have wanted their cDNA microarray to have a SEQ ID NO:1-encoding polynucleotide probe] because a microarray that contained such a probe (as compared to one that did not) would provide more useful results in the kind of gene expression monitoring studies using cDNA microarrays that persons skilled in the art have been doing since well prior to August 30, 2000” (Bedilion Declaration, ¶ 15, item (f)). This, by itself, provides more than sufficient reason to compel the conclusion that the Walker '253 application disclosed to persons skilled in the art at the time of its filing substantial, specific and credible real-world utilities for the claimed polynucleotide.

Nowhere does the Patent Examiner address the fact that, as described on p. 11 of the Walker '253 application, the claimed polynucleotides can be used as highly specific probes in, for example, cDNA microarrays – probes that without question can be used to measure both the existence and amount of complementary RNA sequences known to be the expression products of the claimed polynucleotides. The claimed invention is not, in that regard, some random sequence

whose value as a probe is speculative or would require further research to determine.

Given the fact that the claimed polynucleotide is known to be expressed, its utility as a measuring and analyzing instrument for expression levels is as indisputable as a scale's utility for measuring weight. This use as a measuring tool, regardless of how the expression level data ultimately would be used by a person of ordinary skill in the art, by itself demonstrates that the claimed invention provides an identifiable, real-world benefit that meets the utility requirement. *Raytheon v. Roper*, 724 F.2d 951, (Fed. Cir. 1983) (claimed invention need only meet one of its stated objectives to be useful); *In re Cortwright*, 165 F.3d 1353, 1359 (Fed. Cir. 1999) (how the invention works is irrelevant to utility); MPEP § 2107 ("Many research tools such as gas chromatographs, screening assays, and nucleotide sequencing techniques have a clear, specific, and unquestionable utility (e.g., they are useful in analyzing compounds)" (emphasis added)).

The Bedilion Declaration shows that a number of pre-August 30, 2000 publications confirm and further establish the utility of cDNA microarrays in a wide range of drug development gene expression monitoring applications at the time the Walker '253 application was filed (Bedilion Declaration ¶¶ 10-14; Bedilion Exhibits A-G). Indeed, Brown and Shalon U.S. Patent No. 5,807,522 (the Brown '522 patent, Bedilion Exhibit D), which issued from a patent application filed in June 1995 and was effectively published on December 29, 1995 as a result of the publication of a PCT counterpart application, shows that the Patent Office recognizes the patentable utility of the cDNA technology developed in the early to mid-1990s. As explained by Dr. Bedilion, among other things (Bedilion Declaration, ¶ 12):

The Brown '522 patent further teaches that the "[m]icroarrays of immobilized nucleic acid sequences prepared in accordance with the invention" can be used in "numerous" genetic applications, including "monitoring of gene expression" applications (see Bedilion Tab D at col. 14, lines 36-42). The Brown '522 patent teaches (a) monitoring gene expression (i) in different tissue types, (ii) in different disease states, and (iii) in response to different drugs, and (b) that arrays disclosed therein may be used in toxicology studies (see Bedilion Tab D at col. 15, lines 13-18 and 52-58 and col. 18, lines 25-30).

Literature reviews published shortly before the filing of the Walker '253 application describing the state of the art further confirm the claimed invention's utility. Rockett et al. confirm, for example, that the claimed invention is useful for differential expression analysis regardless of how expression is regulated:

Despite the development of multiple technological advances which have recently brought the field of gene expression profiling to the forefront of molecular analysis, recognition of the importance of differential gene expression and characterization of differentially expressed genes has existed for many years.

* * *

Although differential expression technologies are applicable to a broad range of models, perhaps their most important advantage is that, in most cases, absolutely no prior knowledge of the specific genes which are up- or down-regulated is required.

* * *

Whereas it would be informative to know the identity and functionality of all genes up/down regulated by . . . toxicants, this would appear a longer term goal However, the current use of gene profiling yields a *pattern* of gene changes for a xenobiotic of unknown toxicity which may be matched to that of well characterized toxins, thus alerting the toxicologist to possible *in vivo* similarities between the unknown and the standard, thereby providing a platform for more extensive toxicological examination. (emphasis added)

Rockett et al., Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential, 29 Xenobiotica No. 7, 655 (1999).

In another pre-August 30, 2000 article, Lashkari et al. state explicitly that sequences that are merely “predicted” to be expressed (predicted Open Reading Frames, or ORFs) – the claimed invention in fact is known to be expressed – have numerous uses:

Efforts have been directed toward the amplification of each predicted ORF or any other region of the genome ranging from a few base pairs to several kilobase pairs. There are many uses for these amplicons– they can be cloned into standard vectors or specialized expression vectors, or can be cloned into other specialized vectors such as those used for two-hybrid analysis. The amplicons can also be used directly by, for example, arraying onto glass for expression analysis, for DNA binding assays, or for any direct DNA assay.

Lashkari et al., Whole genome analysis: Experimental access to all genome sequenced segments through larger-scale efficient oligonucleotide synthesis and PCR, 94 Proc. Nat. Acad. Sci. 8945 (Aug. 1997) (emphasis added).

B. The use of nucleic acids coding for proteins expressed by humans as tools for toxicology testing, drug discovery, and the diagnosis of disease is now “well-established”

The technologies made possible by expression profiling and the DNA tools upon which they rely are now well-established. The technical literature recognizes not only the prevalence of these technologies, but also their unprecedented advantages in drug development, testing and safety assessment. These technologies include toxicology testing, as described by Bedilion in his Declaration.

Toxicology testing is now standard practice in the pharmaceutical industry. See, *e.g.*, John C. Rockett et al., *supra*:

Knowledge of toxin-dependent regulation in target tissues is not solely an academic pursuit as much interest has been generated in the pharmaceutical industry to harness this technology in the early identification of toxic drug candidates, thereby shortening the developmental process and contributing substantially to the safety assessment of new drugs.

To the same effect are several other scientific publications, including Emile F. Nuwaysir et al., Microarrays and Toxicology: The Advent of Toxicogenomics, 24 Molecular Carcinogenesis 153 (1999); Sandra Steiner and N. Leigh Anderson, Expression profiling in toxicology -- potentials and limitations, 112-13 Toxicology Letters 467 (2000).

Nucleic acids useful for measuring the expression of whole classes of genes are routinely incorporated for use in toxicology testing. Nuwaysir et al. describes, for example, a Human ToxChip comprising 2089 human clones, which were selected

for their well-documented involvement in basic cellular processes as well as their responses to different types of toxic insult. Included on this list are DNA replication and repair genes, apoptosis genes, and genes responsive to PAHs and dioxin-like compounds, peroxisome proliferators, estrogenic compounds, and oxidant stress. Some of the other categories of genes include transcription factors, oncogenes, tumor suppressor genes, cyclins, kinases, phosphatases, cell adhesion and motility genes, and homeobox genes. Also included in this group are 84 housekeeping genes, whose hybridization intensity is averaged and used for signal normalization of the other genes on the chip.

See also Table 1 of Nuwaysir et al. (listing additional classes of genes deemed to be of special interest in making a human toxicology microarray).

The more genes that are available for use in toxicology testing, the more powerful the technique. “Arrays are at their most powerful when they contain the entire genome of the species

they are being used to study.” John C. Rockett and David J. Dix, Application of DNA Arrays to Toxicology, 107 Environ. Health Perspec.681, No. 8 (1999). Control genes are carefully selected for their stability across a large set of array experiments in order to best study the effect of toxicological compounds. See attached email from the primary investigator on the Nuwaysir paper, Dr. Cynthia Afshari, to an Incyte employee, dated July 3, 2000, as well as the original message to which she was responding, indicating that even the expression of carefully selected control genes can be altered. Thus, there is no expressed gene which is irrelevant to screening for toxicological effects, and all expressed genes have a utility for toxicological screening.

In fact, the potential benefit to the public, in terms of lives saved and reduced health care costs, are enormous. Recent developments provide evidence that the benefits of this information are already beginning to manifest themselves. Examples include the following:

- In 1999, CV Therapeutics, an Incyte collaborator, was able to use Incyte gene expression technology, information about the structure of a known transporter gene, and chromosomal mapping location, to identify the key gene associated with Tangiers disease. This discovery took place over a matter of only a few weeks, due to the power of these new genomics technologies. The discovery received an award from the American Heart Association as one of the top 10 discoveries associated with heart disease research in 1999.
- In an April 9, 2000, article published by the Bloomberg news service, an Incyte customer stated that it had reduced the time associated with target discovery and validation from 36 months to 18 months, through use of Incyte’s genomic information database. Other Incyte customers have privately reported similar experiences. The implications of this significant saving of time and expense for the number of drugs that may be developed and their cost are obvious.
- In a February 10, 2000, article in the *Wall Street Journal*, one Incyte customer stated that over 50 percent of the drug targets in its current pipeline were derived from the Incyte database. Other Incyte customers have privately reported similar experiences. By doubling the number of targets available to pharmaceutical researchers, Incyte genomic information has demonstrably accelerated the development of new drugs.

Because the Patent Examiner failed to address or consider the “well-established” utilities for the claimed invention in toxicology testing, drug development, and the diagnosis of disease, the Examiner’s rejections should be overturned regardless of their merit.

C. The similarity of the polypeptide encoded by the claimed invention to another polypeptide of undisputed utility demonstrates utility

In addition to having substantial, specific and credible utilities in numerous gene expression monitoring applications, the utility of the claimed polynucleotide can be imputed based on the relationship between the polypeptide it encodes, GRIIP, and another polypeptide of unquestioned utility, HW051. The two polypeptides have sufficient similarities in their sequences that a person of ordinary skill in the art would recognize more than a reasonable probability that the polypeptide encoded for by the claimed invention has utility similar to HW051. Appellants need not show any more to demonstrate utility. *In re Brana*, 51 F.3d at 1567.

It is undisputed, and readily apparent from the patent application, that the polypeptide encoded for by the claimed polynucleotide shares more than 79% sequence identity over 464 amino acid residues with HW051. See specification, at p. 10. In addition, the two proteins share various structural and functional sequence motifs, including three transmembrane domains and have similar hydrophilicity profiles. This is more than enough homology to demonstrate a reasonable probability that the utility of HW051 can be imputed to the claimed invention (through the polypeptide it encodes). It is well-known that the probability that two unrelated polypeptides share more than 40% sequence homology over 70 amino acid residues is exceedingly small. Brenner et al., *Proc. Natl. Acad. Sci.* 95:6073-78 (1998). Given homology in excess of 40% over many more than 70 amino acid residues, the probability that the polypeptide encoded for by the claimed polynucleotide is related to HW051 is, accordingly, very high.

The Examiner must accept the applicants' demonstration that the homology between the polypeptide encoded for by the claimed invention and HW051 demonstrates utility by a reasonable probability unless the Examiner can demonstrate through evidence or sound scientific reasoning that a person of ordinary skill in the art would doubt utility. See *In re Langer*, 503 F.2d 1380, 1391-92, 183 USPQ 288 (CCPA 1974). The Examiner has not provided sufficient evidence or sound scientific reasoning to the contrary. The Examiner merely states that applicants assertion that this sequence has homology to another protein that is associated with kidney does not mean that this sequence will have the same association (Final Office Action, p.

4). The Examiner appears to miss the point that the significant association of the HW051 protein, and hence likely of GRIIP as well, is with tissue injury, not necessarily limited to kidney, and therefore likely with inflammation.

D. Objective evidence corroborates the utilities of the claimed invention

There is, in fact, no restriction on the kinds of evidence a Patent Examiner may consider in determining whether a “real-world” utility exists. Indeed, “real-world” evidence, such as evidence showing actual use or commercial success of the invention, can demonstrate conclusive proof of utility. *Raytheon v. Roper*, 220 USPQ2d 592 (Fed. Cir. 1983); *Nestle v. Eugene*, 55 F.2d 854, 856, 12 USPQ 335 (6th Cir. 1932). Indeed, proof that the invention is made, used or sold by any person or entity other than the patentee is conclusive proof of utility. *United States Steel Corp. v. Phillips Petroleum Co.*, 865 F.2d 1247, 1252, 9 USPQ2d 1461 (Fed. Cir. 1989).

Over the past several years, a vibrant market has developed for databases containing all expressed genes (along with the polypeptide translations of those genes), in particular genes having medical and pharmaceutical significance such as the instant sequence. (Note that the value in these databases is enhanced by their completeness, but each sequence in them is independently valuable.) The databases sold by Appellants’ assignee, Incyte, include exactly the kinds of information made possible by the claimed invention, such as tissue and disease associations. Incyte sells its database containing the claimed sequence and millions of other sequences throughout the scientific community, including to pharmaceutical companies who use the information to develop new pharmaceuticals.

Both Incyte’s customers and the scientific community have acknowledged that Incyte’s databases have proven to be valuable in, for example, the identification and development of drug candidates. As Incyte adds information to its databases, including the information that can be generated only as a result of Incyte’s discovery of the claimed polynucleotide and its use of that polynucleotide on cDNA microarrays, the databases become even more powerful tools. Thus the claimed invention adds more than incremental benefit to the drug discovery and development process.

III. The Patent Examiner's Rejections Are Without Merit

A. Membership in a Class of Useful Products Can Be Proof of Utility

Despite the uncontradicted evidence that the claimed polynucleotides are expressed polynucleotides, the Examiner refused to impute the utility of the members of the family of expressed polypeptides to the claimed polynucleotides. In the Final Office Action, the Patent Examiner takes the position that, unless Appellants can identify a specific diagnostic test enabled by the claimed polynucleotides, enablement cannot be imputed. See Final Office Action, at page 5.

In order to demonstrate utility by membership in a class, the law requires only that the class not contain a substantial number of useless members. So long as the class does not contain a substantial number of useless members, there is sufficient likelihood that the claimed invention will have utility, and a rejection under 35 U.S.C. § 101 (and hence a rejection under 35 U.S.C. § 112, first paragraph, based on lack of an enabled use) is improper. That is true regardless of how the claimed invention ultimately is used and whether or not the members of the class possess one utility or many. See *Brenner v. Manson*, 383 U.S. 519, 532 (1966); *Application of Kirk*, 376 F.2d 936, 943 (CCPA 1967).

Membership in a "general" class is insufficient to demonstrate utility only if the class contains a sufficient number of useless members such that a person of ordinary skill in the art could not impute utility by a substantial likelihood. There would be, in that case, a substantial likelihood that the claimed invention is one of the useless members of the class. In the few cases in which class membership did not prove utility by substantial likelihood, the classes did in fact include predominately useless members. *E.g.*, *Brenner* (man-made steroids); *Kirk* (same); *Natta* (man-made polyethylene polymers).

The Examiner addresses the claimed polynucleotides as if the general class in which it is included is not the family of expressed polynucleotides, but rather all polynucleotides, including the vast majority of useless theoretical molecules not occurring in nature, and thus not pre-selected by nature to be useful. While these "general classes" may contain a substantial number of useless members, the family of expressed polynucleotides does not. The family of expressed polynucleotides is sufficiently specific to rule out any reasonable possibility that the claimed

polynucleotides would not also be useful like the other members of the family.

Because the Examiner has not presented any evidence that the family of expressed polynucleotides has any, let alone a substantial number, of useless members, the Examiner must conclude that there is a "substantial likelihood" that the claimed polynucleotides are useful.

B. Because the uses of the claimed polynucleotides in toxicology testing, drug discovery, and disease diagnosis are practical uses beyond mere study of the invention itself, the claimed invention has substantial utility.

As used in toxicology testing, drug discovery, and disease diagnosis, the claimed invention has a beneficial use in research other than studying the claimed invention or its protein products. It is a tool, rather than an object, of research. The data generated in gene expression monitoring using the claimed invention as a tool is **not** used merely to study the claimed polynucleotide itself, but rather to study properties of tissues, cells, and potential drug candidates and toxins. Without the claimed invention, the information regarding the properties of tissues, cells, drug candidates and toxins is less complete. (Bedilion Declaration at ¶ 15.)

The claimed invention has numerous additional uses as a research tool, each of which alone is a "substantial utility." These include uses in chromosomal mapping. See specification, at p. 30, Example VII.

D. The Patent Examiner Failed to Demonstrate That a Person of Ordinary Skill in the Art Would Reasonably Doubt the Utility and hence the enablement of the Claimed Invention

The Examiner states in the Final Office Action, at p. 4 that the Examiner is not rejecting the possible utility of the sequence but the burden of experimentation need to make a specific diagnostic test. Yet the Examiner makes other references to the utility of the invention throughout the enablement rejection, i.e., "one skilled in the art would have reason to doubt the usefulness of the DNA (or protein) for diagnosis or treatment of diseases or disorders associated with inflammation and the immune response" (Office Action, mailed May 31, 2002, pp. 3-4); and "Therefore, the asserted use (of the claimed polynucleotides) for diagnosis of cancer is not credible" (Final Office Action, p. 6). Applicants have therefore addressed their arguments to the enablement rejection, in part, to the claimed utility based on the likelihood that if a specific and substantial utility for the claimed invention is readily apparent from the specification, one skilled

in the art would clearly know how to use it for its intended purpose.

Applicants have already addressed the likelihood of a well-established utility for the claimed invention as a marker for tissue injury based on the homology of the encoded polypeptide to another tissue injury associated polypeptide, HW051. In addition, the specification discloses that the likely association of GRIIP with tissue injury and inflammation is further enhanced by comparative tissue analysis (e.g., Northern analysis) showing its predominate expression in inflamed and cancerous tissues. In particular, GRIIP was expressed in a bone marrow cell line and in cancerous spleen, but was undetectable in various samples of normal tissue from these sources.

In the Final Office Action, the Examiner refutes this data alleging that the fact that the sequence is found in cDNA libraries does not prove a specific relationship/association with a particular disease state (emphasis added). Applicant has not shown that this sequence can be a diagnostic of an individual or used in testing a defined population of people who are to be screened for cancers (emphasis added). The Examiner further stated that, contrary to applicants argument, the determination of a cancer marker must be based on studying results from a considerable number of patients, and statistical analysis. The Examiner then cited Guidelines for Marker Development by the National Cancer Institute in support of these alleged requirements for enablement of applicants claims. See Final Office Action, at page 4.

The Examiner appears to require that the standards for a Food and Drug Administration (FDA), NDA (New Drug Application) application be applied to the utility and enablement requirements for a patent application in this case. Such has never been the standard to support utility and enablement to Appellants knowledge. As previously discussed in § I, above, the standard for utility is "substantial likelihood" or proof to a "reasonable probability", certainty is not required. *Brenner*, 383 U.S. at 532.

IV. By Requiring the Patent Applicant to Assert a Particular or Unique Utility, the Patent Examination Utility Guidelines and Training Materials Applied by the Patent Examiner Misstate the Law

There is an additional, independent reason to overturn the rejections: to the extent the rejections are based on Revised Interim Utility Examination Guidelines (64 FR 71427, December 21, 1999), the final Utility Examination Guidelines (66 FR 1092, January 5, 2001)

and/or the Revised Interim Utility Guidelines Training Materials (USPTO Website www.uspto.gov, March 1, 2000), the Guidelines and Training Materials are themselves inconsistent with the law.

The Training Materials, which direct the Examiners regarding how to apply the Utility Guidelines, address the issue of specificity with reference to two kinds of asserted utilities: “specific” utilities which meet the statutory requirements, and “general” utilities which do not. The Training Materials define a “specific utility” as follows:

A [specific utility] is *specific* to the subject matter claimed. This contrasts to *general* utility that would be applicable to the broad class of invention. For example, a claim to a polynucleotide whose use is disclosed simply as “gene probe” or “chromosome marker” would not be considered to be specific in the absence of a disclosure of a specific DNA target. Similarly, a general statement of diagnostic utility, such as diagnosing an unspecified disease, would ordinarily be insufficient absent a disclosure of what condition can be diagnosed.

The Training Materials distinguish between “specific” and “general” utilities by assessing whether the asserted utility is sufficiently “particular,” *i.e.*, unique (Training Materials at p.52) as compared to the “broad class of invention.” (In this regard, the Training Materials appear to parallel the view set forth in Stephen G. Kunin, Written Description Guidelines and Utility Guidelines, 82 J.P.T.O.S. 77, 97 (Feb. 2000) (“With regard to the issue of specific utility the question to ask is whether or not a utility set forth in the specification is *particular* to the claimed invention.”)).

Such “unique” or “particular” utilities never have been required by the law. To meet the utility requirement, the invention need only be “practically useful,” *Natta*, 480 F.2d 1 at 1397, and confer a “specific benefit” on the public. *Brenner*, 383 U.S. at 534. Thus, incredible “throw-away” utilities, such as trying to “patent a transgenic mouse by saying it makes great snake food,” do not meet this standard. Karen Hall, Genomic Warfare, *The American Lawyer* 68 (June 2000) (quoting John Doll, Chief of the Biotech Section of USPTO).

This does not preclude, however, a general utility, contrary to the statement in the Training Materials where “specific utility” is defined (page 5). Practical real-world uses are not limited to uses that are unique to an invention. The law requires that the practical utility be “definite,” not particular. *Montedison*, 664 F.2d at 375. Appellant is not aware of any court that has rejected an assertion of utility on the grounds that it is not “particular” or “unique” to the

specific invention. Where courts have found utility to be too “general,” it has been in those cases in which the asserted utility in the patent disclosure was not a practical use that conferred a specific benefit. That is, a person of ordinary skill in the art would have been left to guess as to how to benefit at all from the invention. In *Kirk*, for example, the CCPA held the assertion that a man-made steroid had “useful biological activity” was insufficient where there was no information in the specification as to how that biological activity could be practically used. *Kirk*, 376 F.2d at 941.

The fact that an invention can have a particular use does not provide a basis for requiring a particular use. See *Brana, supra* (disclosure describing a claimed antitumor compound as being homologous to an antitumor compound having activity against a “particular” type of cancer was determined to satisfy the specificity requirement). “Particularity” is not and never has been the *sine qua non* of utility; it is, at most, one of many factors to be considered.

As described *supra*, broad classes of inventions can satisfy the utility requirement so long as a person of ordinary skill in the art would understand how to achieve a practical benefit from knowledge of the class. Only classes that encompass a significant portion of nonuseful members would fail to meet the utility requirement. *Supra* § II.B.2 (*Montedison*, 664 F.2d at 374-75).

The Training Materials fail to distinguish between broad classes that convey information of practical utility and those that do not, lumping all of them into the latter, unpatentable category of “general” utilities. As a result, the Training Materials paint with too broad a brush. Rigorously applied, they would render unpatentable whole categories of inventions that heretofore have been considered to be patentable and that have indisputably benefitted the public, including the claimed invention. See *supra* § II.B. Thus the Training Materials cannot be applied consistently with the law.

(9) CONCLUSION

Appellants respectfully submit that rejections for lack of utility, and hence of enablement, based, *inter alia*, on an allegation of “lack of specificity,” as set forth in the Office Action and as justified in the Revised Interim and final Utility Guidelines and Training Materials, are not supported in the law. Neither are they scientifically correct, nor supported by any evidence or sound scientific reasoning. These rejections are alleged to be founded on facts in court cases

such as *Brenner* and *Kirk*, yet those facts are clearly distinguishable from the facts of the instant application, and indeed most if not all nucleotide and protein sequence applications.

Nevertheless, the PTO is attempting to mold the facts and holdings of these prior cases, "like a nose of wax," to target rejections of claims to polypeptide and polynucleotide sequences where biological activity information has not been proven by laboratory experimentation, and they have done so by ignoring perfectly acceptable utilities fully disclosed in the specification as well as well-established utilities known to those of skill in the art. As is disclosed in the specification, and even more clearly, as one of ordinary skill in the art would understand, the claimed invention has well-established, specific, substantial and credible utilities. The rejections are, therefore, improper and should be reversed.

Moreover, to the extent the above rejections were based on the Revised Interim and final Examination Guidelines and Training Materials, those portions of the Guidelines and Training Materials that form the basis for the rejections should be determined to be inconsistent with the law.

Due to the urgency of this matter, including its economic and public health implications, an expedited review of this appeal is earnestly solicited.

If the USPTO determines that any additional fees are due, the Commissioner is hereby authorized to charge Deposit Account No. **09-0108**.

This brief is enclosed in triplicate.

Respectfully submitted,

INCYTE CORPORATION

Date: June 4, 2003

David G. Streeter

David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

Enclosures:

1. Rockett et al., Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential, 29 Xenobiotica No. 7, 655 (1999).
2. Lashkari et al., Whole genome analysis: Experimental access to all genome sequenced segments through larger-scale efficient oligonucleotide synthesis and PCR, 94 Proc. Nat. Acad. Sci. 8945 (Aug. 1997).
3. Emile F. Nuwaysir et al., Microarrays and Toxicology: The Advent of Toxicogenomics, 24 Molecular Carcinogenesis 153 (1999).
4. Sandra Steiner and N. Leigh Anderson, Expression profiling in toxicology -- potentials and limitations, 112-13 Toxicology Letters 467 (2000).
5. John C. Rockett and David J. Dix, Application of DNA Arrays to Toxicology, 107 Environ. Health Perspec. 681, No. 8 (1999).
6. Email from the primary investigator on the Nuwaysir paper, Dr. Cynthia Afshari, to an Incyte employee, dated July 3, 2000, as well as the original message to which she was responding.
7. Brenner et al., Proc. Natl. Acad. Sci. 95:6073-78 (1998).

APPENDIX - CLAIMS ON APPEAL

1. (Once Amended) An isolated cDNA, or the complement thereof, comprising a sequence encoding a protein selected from:
 - a) an amino acid sequence of SEQ ID NO:1;
 - b) an antigenic fragment of SEQ ID NO:1 from about amino acid residue I18 to about amino acid residue V44, from about amino acid residue T145 to Q154, from about amino acid residue L163 to Q200, or from about amino acid residue Q206 to K277 of SEQ ID NO:1; and
 - c) a naturally occurring variant of SEQ ID NO:1 having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:1.
2. (Once Amended) An isolated cDNA comprising a sequence selected from:
 - a) a nucleic acid sequence of SEQ ID NO:2 or the complement thereof;
 - b) a fragment of SEQ ID NO:2 selected from SEQ ID NOs:3-10 or the complement thereof; and
 - c) a variant of SEQ ID NO:2 selected from SEQ ID NOs:11-13.
3. A composition comprising the cDNA or the complement of the cDNA of claim 1.
4. A vector comprising the cDNA of claim 1.
5. A host cell comprising the vector of claim 4.
6. A method for using a cDNA to produce a protein, the method comprising:
 - a) culturing the host cell of claim 5 under conditions for protein expression; and
 - b) recovering the protein from the host cell culture.